Abstract-The population health effect and cost-effectiveness of implementing intensive blood pressure goals in highcardiovascular disease (CVD) risk adults have not been described. Using the CVD Policy Model, CVD events, treatment costs, quality-adjusted life years, and drug and monitoring costs were simulated over 2016 to 2026 for hypertensive patients aged 35 to 74 years. We projected the effectiveness and costs of hypertension treatment according to the 2003 Joint National Committee (JNC)-7 or 2014 JNC8 guidelines, and then for adults aged ≥50 years, we assessed the costeffectiveness of adding an intensive goal of systolic blood pressure <120 mm Hg for patients with CVD, chronic kidney disease, or 10-year CVD risk ≥15%. Incremental cost-effectiveness ratios <$50 000 per quality-adjusted life years gained were considered cost-effective. JNC7 strategies treat more patients and are more costly to implement compared with JNC8 strategies. Adding intensive systolic blood pressure goals for high-risk patients prevents an estimated 43 000 and 35 000 annual CVD events incremental to JNC8 and JNC7, respectively. Intensive strategies save costs in men and are costeffective in women compared with JNC8 alone. At a willingness-to-pay threshold of $50 000 per quality-adjusted life years gained, JNC8+intensive had the highest probability of cost-effectiveness in women (82%) and JNC7+intensive the highest probability of cost-effectiveness in men (100%). Assuming higher drug and monitoring costs, adding intensive goals for high-risk patients remained consistently cost-effective in men, but not always in women. Among patients aged 35 to 74 years, adding intensive blood pressure goals for high-risk groups to current national hypertension treatment guidelines prevents additional CVD deaths while saving costs provided that medication costs are controlled. (Hypertension.
F
or ≈4 decades, the Joint National Committee (JNC) on the Detection, Evaluation and Treatment of High Blood Pressure (BP) supported formulation of US hypertension treatment guidelines. From 1977 to 2003 (JNC1 to JNC7), the guidelines progressively lowered diagnostic thresholds and treatment targets, effectively expanding the treatment-eligible population. The 2014 hypertension guidelines (referred to here as JNC8) recommended higher BP goals compared with JNC7, so that ≈5.8 million fewer adults were eligible for antihypertensive medication treatment.
1,2 JNC8's less intensive BP goal recommendations for patients aged ≥60 years and those with diabetes mellitus or chronic kidney disease (CKD) provoked controversy and uncertainty. 3 More recently, the Systolic Blood Pressure Intervention Trial (SPRINT) found that targeting an intensive systolic BP (SBP) goal of 120 mm Hg in patients with high cardiovascular disease (CVD) risk and baseline SBP ≥130 mm Hg reduced CVD events by 25% and all-cause mortality by 27%, compared with a 140-mm Hg goal. high medication prices. Patients aged ≥75 years were excluded from this analysis because of uncertainty about the tradeoff of risks and benefits of antihypertensive therapy in that population.
Methods

CVD Policy Model
The CVD policy model is a computer-simulation, state-transition (Markov cohort) model of incidence, prevalence, mortality, and costs of CVD in US adults (Methods section in the online-only Data Supplement). 5, 6 Means or proportions and joint distributions of risk factors, including BP, cholesterol, hypertension medication use, smoking, diabetes mellitus, and CKD status were estimated from pooled National Health and Nutrition Examination Surveys (NHANES) 2007 to 2010. Default multivariate stroke and coronary heart disease incidence functions were estimated in original Framingham Heart Study analyses.
The CVD policy model predicts life years, CVD events (myocardial infarction and stroke), coronary revascularization procedures, CVD mortality (stroke [International Classification of Diseases-10 codes I60-I69], coronary heart disease [I20-I25 and two thirds of I49, I50, and I51], hypertensive heart disease deaths [I11.0 and I11.9]), and non-CVD deaths (remainder of International Classification of Diseases codes). Reductions in heart failure deaths because of hypertension treatment were calculated by adding prevented ischemic heart failure deaths (I50 with coronary heart disease) and hypertensive heart disease deaths (I11.0 and I11.9; Methods section in the online-only Data Supplement).
Model Calibration and Validation
Default model input parameters were calibrated, so that 2010 coronary heart disease and stroke incidence predictions matched hospitalized myocardial infarction and stroke rates observed in the 2010 National Hospital Discharge Survey, and mortality predictions were within 1% of age-specific 2010 CVD vital statistics mortality rates. Age-and sex-specific SBP and diastolic BP β-coefficients from the Prospective Studies Collaboration 7 were calibrated, so that CVD Policy Model age-weighted relative risks with BP reduction fell within the 95% confidence interval of the overall relative risk estimates for the same BP reduction observed in a large meta-analysis of randomized controlled hypertension treatment trials (Methods section in the online-only Data Supplement; Tables S1-S3 in the online-only Data Supplement). 8 To test predictive validity, we populated the model with the Systolic Hypertension in the Elderly Program (SHEP) trial cohort and simulated the BP reduction achieved in the active treatment arm of the trial for 5-years of follow-up. Our estimates accurately reproduced the risk reduction observed in the original trial (Table 1 ; Methods section in the online-only Data Supplement; Table S4 ). 9 
Model Inputs
JNC7 recommended a goal BP <130/80 mm Hg for diabetes mellitus or CKD and BP <140/90 mm Hg for all others. JNC8 recommended a goal <140/90 mm Hg for diabetes mellitus or CKD, diastolic BP <90 mm Hg if age is <60 years, and BP <150/90 mm Hg if age is ≥60 years and without diabetes mellitus or CKD. On the basis of SPRINT, intensive interventions were applied to adults aged ≥50 years with pretreatment SBP ≥130 mm Hg and either existing CVD, CKD, or 2013 American Heart Association/American College of Cardiology Pooled Cohorts 10-year CVD risk ≥15%. Using these categories and BP and treatment status information from NHANES, we estimated the number of currently untreated US adults eligible for treatment under JNC7 and JNC8 with and without the intensive intervention in selected high-CVD risk individuals (Table S5) .
BP change caused by antihypertensive medications was determined by pretreatment BP and the number of standard doses of medications needed to reach the guideline BP goal according to a trial-based formula. 10 BP changes were calculated based on pretreatment BP, age, and sex. We assumed the same BP reduction per standard dose of the main drug classes and did not include non-BP-lowering benefits of specific agents (Table 1 ; Methods section in the online-only Data Supplement; Table S5 ). 8, 10 We expected that CVD risk is reduced log linearly in relation to BP reduction (mm Hg) down to SBP 120 mm Hg in high-CVD risk patients in intensive strategies, 130/80 mm Hg in select JNC7 groups (diabetes mellitus or CKD), and SBP 140 mm Hg in those aged 60 to 74 years but without diabetes mellitus or CKD. 8, 10, 11 Hypertension treatment costs included monitoring, side effect, and averaged wholesale drug costs. Quality of life penalties were applied for side effects. 10 A medication adherence rate of 75% estimated in a meta-analysis of clinical trials was assumed because it corresponded to risk reduction associated with treatment estimated in the same meta-analysis (Table 1) . 8 A status quo simulation projected CVD events, CVD deaths, heart failure deaths, costs, and quality-adjusted life years (QALYs) for adults aged 35 to 74 years with untreated hypertension from 2016 to 2026. Adults aged ≥75 years were excluded from this analysis because of variable medication-related adverse event risk in this group. 12 Guideline simulations modeled treatment according to JNC7 or JNC8. Incremental to JNC7 or JNC8, intensive strategies targeted an SBP of 120 mm Hg goal in high-CVD risk patients, limiting to 5 antihypertensive drugs maximum. 4 Incremental cost-effectiveness ratios (ICERs) were calculated as change in costs divided by incremental change in QALYs. ICERs <$50 000 per QALY gained were considered cost-effective, ≥$50 000 and <$150 000 of intermediate value, and ≥$150 000 of low value. 13 All analyses were approached from a payer's perspective. Future costs and QALYs were discounted at 3% per year.
Subgroup and Sensitivity Analyses
JNC7 and JNC8 with and without intensive treatment in selected high-CVD risk individuals were compared within age groups. Oneway sensitivity analyses assessed cost-effectiveness assuming lower and upper uncertainty boundaries of the main inputs, including increased monitoring costs for the intensified treatment strategies (Table 1) . We also modeled medication adherence as low as 40%.
14 Main analyses did not include patients with treated but uncontrolled hypertension because it was not clear what proportion of poor control was because of underuse of combination therapy, poor adherence, or resistant hypertension. 6 Nonetheless, we repeated the analyses in the entire population with uncontrolled hypertension, including previously treated and uncontrolled hypertension.
Probabilistic Analyses
Probabilistic (Monte Carlo) simulation sampled across uncertainty distributions of antihypertensive drug BP-lowering effectiveness, CVD relative risk reduction with treatment, quality of life penalties, costs related to side effects, and drug and monitoring costs. Uncertainty distributions were randomly sampled 1000×, and 95% uncertainty intervals were calculated for all model outputs. Costeffectiveness acceptability curves were constructed to illustrate the probability that each hypertension treatment strategy would be costeffective at different willingness-to-pay thresholds.
Results
Main and Probabilistic Results
Compared with no treatment, JNC8 would increase the annual number of newly treated adults aged 35 to 74 years by ≈12 million and would avert ≈65 000 CVD events and 17 000 CVD deaths annually. Compared with JNC8, JNC7 would recommend treatment for nearly twice the number of untreated patients (21 million) and add substantial treatment costs but would avert 24 000 additional CVD events and 5000 additional CVD deaths annually (Table 2) . Incremental to JNC8, JNC8 plus intensive treatment in selected high-risk groups (JNC8+intensive) would prevent 43 000 additional annual CVD events and 15 000 CVD deaths. Incremental to JNC7, JNC7+intensive would lead to 35 000 fewer annual CVD events and 14 000 fewer CVD deaths. Total annual heart failure deaths avoided ranged from ≈2000 under JNC8 alone to ≈4000 under JNC7+intensive (Table S6 in the online-only Data Supplement).
In men, implementing JNC7 in addition to JNC8 would be cost-effective (ICER, ≈$7000 per QALY gained; Table 2 ). Incremental to JNC8, JNC7+intensive and JNC8+intensive strategies would be cost saving in men aged 35 to 74 years. At a willingness to pay threshold of $50 000 per QALY gained, the probability JNC7+intensive was more cost-effective than any other strategy in men was 100% ( Figure 1 , cost-effectiveness acceptability curve). At a lower willingness to pay threshold of <$25 000, JNC8+intensive was more likely to be costeffective than the JNC7+intensive strategy (>50%, probability more cost-effective). In women, JNC7 was borderline costeffective compared with JNC8 (≈$52 000 per QALY gained). Adding intensive treatment of high-risk patients was costeffective in women incremental to JNC8. At a willingness-topay threshold of $50 000 per QALY gained, the probability that JNC8+intensive was the most cost-effective strategy for women ALLHAT indicates Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; GBD, Global Burden of Disease; JNC Joint National Committee; MD, medical doctor; OSHPD, Office of Statewide Health Planning and Development; QALY, quality-adjusted life years; RR, relative risk; and SBP, systolic blood pressure. *RR reductions vary by age and sex category (see Methods and online-only Data Supplement for details). †BP change dependent on age-and sex-specific distribution of baseline blood pressures within stage 1 or stage 2 category and number of standard dose antihypertensive medications.
‡Standard dose medications used to estimate costs: captopril 25 mg twice daily, nifedipine 30 mg daily, amlodipine 5 mg daily, hydrochlorothiazide 25 mg daily, and atenolol 50 mg daily. $21 000/QALY gained ICER <$50 000 per QALY gained is considered cost-effective. CVD indicates cardiovascular disease; ICER, incremental cost-effectiveness ratio; JNC, Joint National Committee; QALY, quality-adjusted life years; SBP, systolic blood pressure; and UI, uncertainty interval.
*Overall CVD death includes heart failure deaths. As heart failure deaths were estimated not simulated, 95% UI do not account for heart failure deaths. †Intensive treatment is defined as an SBP goal of <120 mm Hg in adults aged 50 y and older with SBP ≥130 mm Hg and existing CVD, chronic kidney disease, or 2013 American Heart Association/American College of Cardiology Pooled Cohorts 10-year CVD risk ≥15%. was 81.7%, whereas the probability that the JNC7+intensive strategy most cost-effective was 18.3% ( Figure 2 ).
Subgroup Analyses
Incremental to JNC8, JNC7 would be cost saving in men aged 60 to 74 years, cost-effective in men aged 45 to 59 years (ICER, ≈15 000 per QALY gained) and in women 60 to 74 years (ICER, ≈30 000 per QALY gained), but of intermediate and low value in men and women aged 35 to 44 years, respectively. Incremental to JNC8 alone, JNC8+intensive would be cost saving in all age groups, whereas JNC7+intensive would be cost saving in all men and in women 60 to 74 years old, but cost-effective in women aged 45 to 59 years (ICER, 44 000 per QALY gained; Table S7 ).
Sensitivity Analyses
Assuming 20% less CVD risk reduction per BP change (in mm Hg), more frequent monitoring plus double the drug costs, or 40% medication adherence, adding JNC8+intensive or JNC7+intensive remained cost-saving or cost-effective in most instances (ICERs <$50 000; Table S8 ). High drug costs plus higher monitoring frequency or 40% adherence made JNC7+intensive of intermediate or low value in women. JNC7 alone was sensitive to high drug costs incremental to JNC8.
Adding treatment of treated but uncontrolled hypertension would double the population eligible for treatment to BP control under all strategies and lead to 60 000 to 91 000 fewer CVD events with intensive strategies compared with JNC8 alone. ICERs for the comparison of JNC7 versus JNC8 with and without intensive strategies remained similar when the previously treated and uncontrolled group was added (Table S9 ).
Discussion
We projected that adding intensive strategies to JNC hypertension treatment guidelines would be cost saving in men and cost-effective in women aged 35 to 74 years, which held true even in the event of higher monitoring costs. From a payer's perspective, JNC8+intensive would most likely be the highest value strategy in women, whereas JNC7+intensive would most likely be the highest value strategy for men. The committee appointed by the JNC8 recommended an SBP target of 150 mm Hg among individuals aged 60 years and older and a target of 140 mm Hg for patients with diabetes mellitus or CKD, based on selected hypertension medication treatment trials. SPRINT results were released after the JNC8 published its recommendations and suggested greater CVD benefit from an SBP goal of 120 mm Hg, as opposed to 140 mm Hg in patients at high CVD risk. 4 SPRINT reinforced evidence favoring a lower BP goal in selected high-risk patients. [15] [16] [17] [18] Concerns about the risks of intensive treatment persist. 19, 20 The bulk of randomized trial evidence demonstrates reduction in major CVD events, renal outcomes, and retinopathy from BP lowering well below the 140/90 mm Hg threshold without clear effects on CVD or noncardiovascular death, and the size of these benefits is consistent with epidemiological associations. 8, 21, 22 The more recent Heart Outcomes Prevention Evaluation (HOPE)-3 trial found that BP lowering conferred no appreciable benefit in intermediate risk patients (mean 10-year CVD risk, ≈10%), except for those with pretreatment systolic BP >144 mm Hg. 23 Therefore, treatment of patients with pretreatment systolic BP 130 to 139 mm Hg and 10-year CVD risk <15% according to JNC7 remains controversial.
Our study had several limitations. Hypertension treatment guideline effectiveness and cost-effectiveness may vary among specific population groups with higher hypertension prevalence, such as blacks 16 and subgroups at high risk for CVD, in whom greater benefits may derive from hypertension treatment. Although we estimated the effect of hypertension treatment on ischemic heart failure hospitalizations and deaths, coronary heart disease hospitalizations and deaths involving heart failure are difficult to accurately measure based on International Classification of Diseases-coded data. We projected heart failure deaths prevented because of hypertension treatment, but we did not simulate heart failure incidence or capture heart failure states directly, and we may have underestimated reduced heart failure burden attributable with hypertension treatment. We did not account for non-blood pressure-lowering benefits of certain antihypertensive drug classes, such as angiotensin-converting enzyme inhibitors, in patients with heart failure or past myocardial infarction. We did assume that most CVD patients would require >1 medication to reach the BP goal, one of those being an angiotensin-converting enzyme inhibitor. We may also have underestimated monitoring costs, including personnel, technology, or additional office visits needed to achieve intensive goals.
We followed the decision of the SPRINT trial and did not target an SBP 120 mm Hg goal in patients with diabetes mellitus. Uncertainty persists about benefits and risks of intensive BP lowering in these patients. 24, 25 Intensive BP lowering consistently lowered stroke risk in trials enrolling older patients with diabetes, but results for coronary heart disease were variable. 23, 24 Patients with stroke were excluded from SPRINT; our decision to target intensive BP goals in patients with stroke is supported by suggestion of a benefit from intensive treatment in patients with stroke enrolled in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. 26 SPRINT included participants aged ≥75 years, but we excluded elderly patients from our analysis because of uncertainty about risks and benefits of intensive BP lowering in the frail elderly. 27 JNC recommendations have increased hypertension awareness, treatment, and control in the US population and likely contributed to the decline in CVD mortality during the past 4 decades. 28 Our results suggest that targeting an intensive goal of 120 mm Hg in selected high-CVD risk patients in addition to the standard JNC guidelines would be cost saving if high drug costs can be controlled.
Perspectives
Hypertension treatment is inexpensive, safe, and effective. Guidelines should not be applied blindly, without considering the balance between benefits and harms in individual patients. However, in robust otherwise healthy patients aged <75 years, targeting more intensive blood pressure treatment goals in high CVD risk patients would be cost saving if monitoring and drug costs could be contained. 
SUPPLEMENTARY MATERIAL
SUPPLEMENTARY METHODS
Structure of the Model
The Cardiovascular Disease (CVD) Policy Model is a computer-simulation, state-transition (Markov cohort) model of coronary heart disease and stroke incidence, prevalence, mortality, and costs in the U.S. population over age 35 years.
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The Demographic-Epidemiologic Submodel predicts coronary heart disease and stroke incidence and non-CVD mortality among subjects without CVD, stratified by age, sex, and up to 8 additional categorized risk factors estimated from weighted United States National Health and Nutrition Examination Survey (NHANES) data from 2007-2010. Risk factors include: systolic blood pressure (<140, 140-159.9, ≥160), isolated diastolic blood pressure (normal systolic blood pressure and diastolic blood pressure (90-99 or ≥100 mmHg), antihypertensive medication treatment status (selfreported), smoking status (active smoker, non-smoker with exposure to environmental tobacco smoke, non-smoker without environmental exposure), high density lipoprotein (HDL) cholesterol (<1.0, 1.0-1.5, ≥1.6 mmol/L; <40, 40-59.9, ≥60 mg/dL), low-density lipoprotein (LDL) cholesterol (<2.6, 2.6-3.3, ≥3.4 mmol/L; <100, 100-129.9, ≥130 mg/dL), body mass index (<25, 25-29.9, ≥30 kg/M 2 ), diabetes mellitus (yes or no), and chronic kidney disease [estimated glomerular filtration rate of < 60 ml/min (using the Modifcation of Diet in Renal Disease formula), and/or proteinuria (spot albumin/creatinine ration > 200 μg/g)]. After CVD develops, the Bridge Submodel characterizes the initial stroke or coronary heart disease event (cardiac arrest, myocardial infarction, or angina) and its sequelae for 30 days. Then, the Disease History Submodel predicts subsequent CVD events, coronary revascularization procedures, CVD mortality, and non-CVD mortality among patients with CVD, stratified by age, sex, and history of events. The general chronic CVD categories are coronary heart disease only, stroke only, and combined prior coronary heart disease and prior stroke. Each state and event has an annual cost and quality-of-life adjustment as well as an annual probability of a repeat event and/or transition to a different CVD state. All population distributions, risk factor levels, coefficients, event rates, case fatality rates, costs, and quality-of-life adjustments can be modified for forecasting simulations.
Data Sources
Version 4 of the CVD Policy Model includes data from prior versions as well as many updates and upgrades. [1] [2] [3] The 2010 U.S. Census provides the baseline population 4 and number of 35 year-olds projected to enter the model population from 2010-2060. 5, 6 CHD and stroke deaths in 2010 were extracted from U.S. Vital Statistics. 7 Deaths were categorized according to the International Classification of Diseases (ICD) 10 codes 8 : I20-I25 and two-thirds of I49, I50, and I51 were used to estimate coronary heart disease deaths, 9 I60-I69 were used to estimate stroke deaths, and all other deaths were considered non-CVD deaths. Ischemic heart failure deaths were calculated based on the proportion of 2010 coronary heart disease deaths with primary ICD-10 codes I50.x.
The incidence of coronary heart disease and stroke were based on competing risk Cox proportional hazards analysis of the Framingham Heart Study 10 and the Framingham Offspring Study 11 cohorts from 1988-2007, with further adjustment for risk factor differences between the Framingham cohorts and the contemporary U.S. population represented by the NHANES. Incident coronary heart disease events were allocated to angina pectoris, hospitalized myocardial infarction, or cardiac arrest. Prevalence, joint distributions and means of U.S. risk factor values were estimated from pooled, survey design-weighted NHANES, 2007-10. 12 Annual transition rates between risk factor levels were calculated to preserve age-range trends over time. Risk function betas for non-blood pressure risk factors were estimated separately for the risk of incident coronary heart disease events, incident strokes , and non-CVD deaths, using examinations 1-8 of the Framingham Offspring cohort. 11 The Framingham coefficients have been useful across many populations. [13] [14] [15] [16] Risk factors were assumed to affect the incidence of myocardial infarction, arrest, and angina in proportion to the overall incidence of coronary heart disease, except tobacco smokers were assumed to have a higher relative risk for infarction and arrest ( 17 ; personal communication, Sean Coady, National Heart, Lung, and Blood Institute, February, 2006 ) and a proportionately lower coefficient for angina. Environmental tobacco exposure was assumed to carry a relative risk of 1.26 for myocardial infarction and cardiac arrest compared with non-exposed non-smokers 18 but not to influence angina.
Baseline CVD Policy Model inputs for the year 2010 were within 1% of all targets obtained from U.S. national data sources (Table S1 ).
Preliminary analyses suggested that the strength of the observational association between blood pressure and CVD risks in the Framingham Heart Study fell short of the strength of association observed in antihypertensive treatment trials (basis of comparison was the Law, Morris, and Wald trials meta-analysis summary estimates) . 19 Starting with CVD Policy Model default blood pressure beta coefficients estimated from Framingham Heart Study data, we calibrated the coefficients in order to 1) reproduce the association of change in systolic BP estimated from both the Prospective Cohort Studies Collaborative, and 2) a large pooled analysis of BP treatment trials by Law, Morris, and Wald. 19 A U.S. NHANES-based cohort representing the age and sex structure and mean systolic BP of the U.S. stage one and stage two hypertensive population was prepared for calibration simulations. In order to simulate the average trial pooled in the Law, Morris and Wald study, five year treatment duration was simulated. First, a base case was simulated for 2010-2014 with no change in 2010 blood pressure levels. A 2010-2014 intervention simulation followed in which systolic BP was lowered by approximately 10 mm Hg or diastolic blood pressure was lowered 5 mm Hg in each age and sex category. Beta coefficients were calibrated until the Prospective Cohort Studies Collaboration age-and sexspecific relative risks were matched within 0.02 or less (Table S2 ). Summary (age and sex weighted) relative risk with a 10 mm Hg systolic or 5 mm Hg diastolic blood pressure change for ages 35-74 years of 0.75 was within the 95% confidence limits of the treatment trials relative risks estimated in the Law, Morris, and Wald meta-analysis for coronary heart disease (target interval 0.73-0.83), as was the estimate for stroke (estimate 0.64; target interval 0.52-0.67; Table S3 ).
In order to ensure that the systolic BP relative risk inputs were not over-fitted to the calibration targets, and not representative of the results of a real clinical trial, we set out to use the model to simulate the landmark Systolic Hypertension in the Elderly Program (SHEP), a double-blind placebo-controlled trial of antihypertensive adults aged 60 and older. By analyzing individual participant-level data, we were able to enter the characteristics of the SHEP intervention arm and control arms (age, baseline systolic BP, mean HDL and LDL cholesterol, and smoking status of participants). We then simulated the SHEP trial over a five-year period (mean follow up in SHEP lasted 4.5 years). Cox proportional hazards analysis of SHEP was performed in order to ensure that we could reproduce the estimates reported in the 1999 SHEP trial report, and we performed original analyses of SHEP data in order estimate the total stroke (fatal and nonfatal), and total and fatal coronary heart disease relative risks associated with BP treatment consistent with CVD Policy Model definitions.
For each of stroke and CHD, we simulated RRs of stroke and CHD, assuming baseline characteristics of the SHEP cohort and systolic blood pressure beta coefficients used in our main analysis (these based on the Prospective Cohort Studies Collaboration and Law, Morris, Wald meta-analysis of trials as described above). Stroke and CHD RRs resulting from the simulated trial were then compared with the main estimates and 95% confidence intervals of the observed effects reported by the SHEP trial (Table S4) .
Compared with the results observed in the actual trial, our five-year simulation of the SHEP trial resulted in nearly perfectly matched results for reductions in the rate of coronary heart disease events with treatment. For stroke, our simulations yielded a 30% reduction in strokes (relative risk 0.70) compared with the 36% reduction observed in the trial (relative risk 0.64). SHEP excluded potential participants if they had a history of atrial fibrillation, but our Model cannot selectively do so. Since five-year effects of antihypertensive treatment are unlikely to lower risk for stroke caused by atrial fibrillation, the inclusion of people with atrial fibrillation likely explains why our simulated reduction of nonfatal stroke was less than that observed in SHEP. If we adjust our total stroke relative risk for an assumed 15% of all strokes (fatal and nonfatal) due to atrial fibrillation, 20 and unaffected by the BP lowering intervention, our simulated trial would yield a relative risk of total stroke of 0.66 (calculated as: exp[1.15*ln(0.70)]), very close to the SHEP total stroke relative risk of 0.64.
The number of hospitalized myocardial infarctions was obtained from discharges coded as ICD-9 code 410 in the 2010 National Hospital Discharge Survey (NHDS) 21 adjusted for likely miscoding, 22 such as patients who were discharged alive after two days or fewer without a percutaneous coronary intervention, and transfer patients. Case-fatality rates and rates of myocardial infarction in subgroups were estimated from national data 21 and a variety of complementary sources. [23] [24] [25] Prehospital arrest deaths were estimated from the U.S. Vital Statistics, 26 and out-of-hospital cardiac arrests surviving to hospital discharge were estimated from national data 21 . Survival after a coronary heart disease event was estimated using California data on the ratio of in-hospital survival to 30 day survival 27 and data from Medicare and Seattle, Washington. 28, 29 Rates of coronary revascularizations were estimated from the National Hospital Discharge Survey, 21 with mortalities estimated from aggregrated historical data.
Stroke incidence was assumed to independent of the risk of new onset coronary heart disease in the same year. The number of hospitalized strokes was also obtained from the 2010 NHDS. Positive predictive values of specific ICD-9 stroke hospital diagnosis codes (inclusive of ICD 9 codes 430-438) were derived by pooling several studies of stroke incidence that compared hospital diagnoses with a gold standard (e.g., stroke ascertained by Atherosclerosis in Communities Study, the Rochester Epidemiology Study or similar criteria). 30 The positive predictive values were applied to age-and sex-specific NHDS cases in order to estimate total stroke event rates (inclusive of first-ever and recurrent stroke events). Applying 30-day case fatality rates based on the Atherosclerosis in Communities Study 31, 32 yielded annual mortality rate estimates within the range of stroke rates reported by the U.S. Centers for Disease Control (CDC Wonder) for 2010. Incidence calibration assumed that 77% of all strokes are incident (first ever), 33 but it was assumed that the proportion first ever/total diminished with age (i.e., >90% of all strokes are first strokes in 35-44 year olds and 50% are first strokes in 85-94 year olds). The resulting incidence of hospitalized stroke approximated age and sex specific stroke incidence rates observed in U.S. stroke cohort and surveillance studies. The annual probabilities of stroke after myocardial infarction 34 and the probability of coronary heart disease in stroke patients was based on natural history studies. [35] [36] [37] [38] [39] [40] The background prevalence of CVD by age, sex, and CVD disease state (stroke, coronary heart disease, or both stroke and coronary heart disease) in 2010 was estimated from the National Health Interview Survey data from [2009] [2010] [2011] 41 assuming that the imperfect positive predictive value of survey data is offset by its imperfect sensitivity. [42] [43] [44] Age-specific prevalences for individual CVD disease states were fitted with polynomial or spline functions of age to obtain smooth, monotonically increasing prevalences. The background prevalence of prior coronary revascularization was estimated from revascularizations before 2010 and estimated survival after revascularization, while model projections were used to infer the distribution of revascularization by CVD state.
Heart failure deaths were estimated by applying age-and sex-specific proportions of hypertensive heart disease (ICD-10 I11.0, I11.9) to extrapolate total ischemic heart disease and congestive heart failure deaths. The proportion of hypertensive heart disease and ischemic heart disease were then used to inflated coronary heart disease deaths similated by the CVD Policy Model and estimate number of heart failure deaths in total.
Age and sex specific health care costs were estimated using national data. 45 Hospitalized stroke and coronary heart disease costs and acute stroke rehabilitation costs were estimated using 2008 California hospital data, 46 deflated using cost to charge ratios 47 and the ratio of the U.S. national average costs to the California average. 48 Chronic outpatient CVD costs additional to average background health care costs for the first year after the event and for subsequent years were estimated for patients with a stroke or coronary heart disease diagnosis surveyed in the U.S. Medical Expenditure Panel Surveys (MEPS) pooled from 1998-2008. Average annual noncardiovascular (background) costs were also estimated from the MEPS. 49 All model costs were indexed to the year 2010 using the medical component of the consumer price index. Healthrelated quality-of-life weights and severity distributions for disease states were based on the Global Burden of Disease disability weights study. [50] [51] pharmacologic treatment were grouped into those with or without diabetes or chronic kidney disease (CKD). The blood pressure targets for those treatment groups are shown in manuscript Table 1 . Those without those conditions were categorized into Nonblack and Black. For initial choice of antihypertensive agent, Nonblack patients were recommended to start with any of thiazide diuretic, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB) or calcium channel blocker (CCB). Black patients were recommended the same initial choice of therapies, except were not recommended to start with an ACE. Patients without diabetes but without CKD were recommended the same options as above for non-diabetics (options based on if the patient is Nonblack or Black). Patients with chronic kidney disease were recommended to start with an ACE or an ARB. Should the patient require more than one medication to reach target blood pressure, the guideline recommended any of the following: 1) maximize the first medication to full dose, then add a second agent; 2) add the second agent before maximizing the dosage of the first, or 3) start with two medication classes in combination. Our analysis used recommendations from the prior national guideline and the observed number of visits needed to achieve hypertension control in the ALLHAT trial (manuscript Table 1 ).
We did not choose to simulate the effects of any particular medication; instead we simulate "standard dose" effects and assumed average drug prices across classes. Examples of standard doses for different antihypertensive medications can be found at http://www.wolfson.qmul.ac.uk/bpchol/a3.pdf, and include nifedipine 30 mg daily, amlodipine 5 mg daily, lisinopril 10 mg daily, hydrochlorothiazide 25 mg daily, and losartan 50 mg daily, Especially in patients with higher BPs (e.g. stage two hypertension), medications are added sequentially and BP lowered gradually over time. The amount of blood pressure change was assumed to be a function of the pre-treatment or baseline BP and the effect of a standard-dose antihypertensive agent at that pre-treatment level (Table S5) . It is important to note that for patients with very high BPs (mean systolic BP of 185 mm Hg or more) it was assumed that even with taking four standard dose medications, these patients would on average achieve a BP of about 143 mm Hg, near, but not at, the target of 140 mmHg. *95% uncertainty intervals derived from 1,000 probabilistic simulations that sampled from within the 95% confidence intervals of age-and sex-specific Prospective Cohorts Studies Collaboration beta coefficients. †SHEP incident coronary heart disease defined as first-in-trial nonfatal acute myocardial infarction, coronary revascularization, or coronary heart disease death. CVD Policy Model incident coronary heart disease defined as first-ever nonfatal acute myocardial infarction, angina pectoris with or without coronary revascularization, or coronary heart disease death. Ischemic heart failure deaths were calculated by applying the proportion of coronary heart disease deaths that are heart failure deaths (based on proportions observed in U.S. vital statistics; see Data Sources section, page 3 of this Materials) to the total number of coronary heart disease deaths. † Intensive treatment is defined as an SBP goal of <120 mmHg in adults aged 50 years and older with SBP ≥ 130 mmHg and existing CVD, chronic kidney disease and/or ACC/AHA 10 year CVDrisk ≥15%.
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